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1. Introduction
Homeostasis in the bone marrow is dependent on the ability of hematopoietic stem cells (HSCs)
to self-renew faithfully, differentiate into various lineages of the hematopoietic system, and
form blood cells of several types (Figure 1) [1,2]. Under homeostatic conditions, HSCs are
thought to be quiescent, and they are referred to as long-term reconstituting HSCs (LT-HSC)
or dormant HSCs (dHSCs) [3,4]. Blood and immune cells are produced by the more differen‐
tiated short-term reconstituting HSCs (ST-HSCs) or multipotent progenitors (MPPs). Genetic
and molecular studies of HSC self-renewal have identified candidate regulatory factors, in‐
cluding cell-intrinsic regulators, such as transcription factors and cell surface receptors, and
cell-extrinsic regulators, such as the bone marrow niche and cytokines. Under certain condi‐
tions, such as inflammatory stress, HSCs differentiate into progenitor cells with less ability to
self-renew, and they can be stimulated to divide and/or differentiate into all cell types in the
peripheral blood [5,6]. Under inflammatory conditions, such as during bacterial infection or
sepsis, an apparent expansion of lineage-negative Sca-1+c-Kit+ bone marrow cells (KSL) has
been observed [7–11]. HSCs and progenitor cells are involved in the expansion of KSL; and
expansion of the KSL population in the bone marrow has been associated with a loss of dor‐
mant LT-HSCs, reduced engraftment, and a bias towards myeloid lineage differentiation
within that population. The process of the transition of HSCs from dormancy to activity is
mediated by type I interferon (IFN) and type II IFN.
Interferon is produced by cells of the immune system in response to challenge by agents, such
as viruses, bacteria, and tumor cells. Type I IFNs are induced by the genomes of many RNA
viruses during viral infection, and they suppress viral replication and have immunomodula‐
tory activity. IFNs are used clinically to treat viral diseases and malignancies, such as chronic
myeloid leukemia (CML)[12]. In addition, under steady state conditions in the absence of in‐
fection, a small amount of intrinsic IFN is produced constitutively [13]. Recently, Essers et al.
demonstrated that chronic activation of the IFN-α pathway impairs the function of HSCs and
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that acute IFN-α treatment promotes the proliferation of dHSCs in vivo. Studies exploring the
application of type I IFN to target cancer stem cells are expected [14].
Figure 1. The fates of hematopoietic stem cells. HSCs are capable of self-renewal and differentiation into various line‐
ages of the hematopoietic system to form all types of blood cells. LT-HSCs, ST-HSCs, and MPP are included in the KSL
population.
Interferon regulatory factor-2 (IRF-2) is a typical inhibitor of the IFN response. Previously, I
showed that IRF-2-/- mouse bone marrow cells contain an enhanced population of Sca-1-pos‐
itive cells and reduced HSC activity in the KSL fraction [15]. Sato et al. reported that a marked
reduction of hematopoietic stem cells in IRF-2-/- mice was dependent on a type I IFN-depend‐
ent mechanism [16]. In IRF-2-/- mouse bone marrow, type I IFN signalling is constitutively
activated, and interferon-stimulated genes (ISGs) are continuously induced to activate cell
cycle progression in HSCs. IRF-2 plays an important role enabling HSCs to maintain their
inhibitory status against the type I IFN response.
Bone marrow HSCs are somatic stem cells that have a number of cell surface markers, which
allow their prospective identification and isolation with FACS. Mouse models are usually used
to examine HSC function in vivo. However, the HSC cell surface markers differ between mice
and humans. Mouse HSCs in healthy adult bone marrow show a Lin-Sca-1+c-Kit+CD34-
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CD150+CD48- phenotype. In contrast, human HSCs are less well defined but present in the
Lin-CD34+CD38- population within cord blood.
Infection or inflammation usually induces IFN production for host defense. Thus, the IFN
response is a key factor in switching HSC activity to renewal in the hematopoietic system
during the response to environmental conditions. This review will focus on the regulation of
HSCs mediated by types I and II IFN.
2. Hematopoietic stem cells in bone marrow
Under homeostatic conditions, HSCs are thought to be quiescent, and they are referred to as
long-term reconstituting HSCs (LT-HSC) or dormant HSCs (dHSCs) [3,4]. During homeostasis,
dormant HSCs(dHSCs) are consistently inactive with residing bone marrow niches. Homeo‐
static HSCs (hHSCs) divide and self-renew to generate the progenitors [14]. dHSCs are almost
in the G0 phase of cell cycle and found in niches within the cavities of trabecular bone. dHSCs
are resistant to anti-proliferative chemotherapy such as 5-fluorouracil (5-FU). Homeostatic
HSCs(hHSCs) divide and self-renew. dHSCs and hHSCs exit their niches and undergo self-
renewing divisions, followed by maintenance to homeostasis of hematopoietic cell popula‐
tions. IFN-α induces cell cycle entry of dHSCs and hHSCs, resulting in rapidly dividing active
HSCs (aHSC), which can produce progenitors and then differentiate ito mature cell types [14].
3. Type I IFN (IFN-α)
IFNs play a critical role in the regulation of resistance to viral infection and activation of the
innate and acquired immune system through IFN-stimulated genes (ISGs). IFNs also have an
anti-malignant effect and are important intrinsic cytokines for host defense. To induce ISGs,
type I IFN signaling is mediated by activation of the Jak-STAT signaling pathway through the
type I IFN receptor (Figure 2). Many RNA viruses and double-stranded RNAs that mimic
polyinosinic-polycytidylic acid (poly[I:C]) induce the expression of type I interferons (IFN-α,
IFN-β) that bind to the IFNα/β receptor (IFNAR), which mediates Jak-STAT signaling followed
by ISG transcription. Treatment with IFN-α induces transcription and cell surface presentation
of stem cell marker Sca-1, which is downstream of IFN-α signaling, on hematopoietic stem
cells and progenitor cells [14].
The KSL population from IRF-2-/- mouse bone marrow is increased due to the enhancement
of Sca-1. However, the CD150+CD48-KSL population is dramatically reduced because of a
reduction of the CD150+ population in IRF-2-/- mouse bone marrow cells. IRF-2-/- HSCs are
incapable of reconstituting lethally irradiated mice because of constitutive IFN signaling.
Chronic exposure to IFN-α has a negative effect on HSC self-renewal. IFN-α induces the acti‐
vation of the dormant HSC pool. Sato et al. indicated that chronic exposure of HSCs from
IRF-2-/- mice to IFN-α resulted in a marked reduction of LT-HSCs and dHSCs[16]. This re‐
duction of LT-HSC activity was rescued in IRF-2-/-IFNAR-/- dKO mice, but not completely,
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suggesting an IFN-independent mechanism exists in IRF-2-/- mice. Gene expression and trans‐
plantation analyses using HSCs from IRF-2-/-IFNAR-/- mice have demonstrated that IRF-2
regulates HSC populations independently of type I IFN signaling.
Figure 2. Jak-Stat signaling pathway activated by Interferon. Type I IFN binds to the IFN receptor to stimulate the Jak-
STAT signaling pathway. Phosphorylated JAK1and Tyk2 phosphorylate STAT1 and STAT2, which heterodimerize via
SH2 domain, and then translocated to nucleolus with IRF-9. The interferon-stimulated gene factor-3 (ISGF3) complex
is transferred to the nucleus to bind to the ISRE consensus sequence that induces transcription, resulting in production
of ISGs. STAT: Signal Transducers and Activator of Transcription, SH2:Src homology domain
A large quantity of whole bone marrow cells from IRF-2-/- mice can rescue recipients from
lethal irradiation [15]. Whole bone marrow cells from IRF-2-/- mice were transplanted into
lethally irradiated wild type mice, and KSL or CD150+CD48-Lin- cells from the recipient mice
were isolated. Higher doses of bone marrow cells from IRF-2-/- mice could rescue recipients
from lethal irradiation, even if the engraftment efficiency was poorer than that of wild-type
mice. In addition, in the rescued recipients, the percentage of donor-derived KSL and
CD150+CD48-Lin- cells from IRF-2-/- mice was higher compared to that of wild-type mice
(Masumi et al., unpublished data).
The  number  of  CD150+CD48-Lin-  cells  from  IRF-2-/-  mouse  bone  marrow present  in  a
recipient  wild-type  environment  is  almost  comparable  to  that  of  wild-type  (Masumi  et
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al.,  unpublished data).  A marked reduction of  CD150+CD48-Lin-  cells  in  the  bone mar‐
row  of  IRF-2-/-  mice  may  be  due  to  the  impairment  of  the  stem  cell  niche  in  IRF-2-/-
mouse  bone  marrow.  Essers  et  al.  reported  that  wild-type  HSC  in  chimeric  mice  with
wild-type hematopoietic cells in an IFNAR-/- stromal environment are still efficiently ac‐
tivated  by  IFN-α  and  that  IFN-α  signaling  is  not  required  in  the  stem  cell  niche.  The
CD150+  population  in  KSL  cells  may  be  partly  regulated  by  an  IRF-2-dependent  stem
cell  niche environment.  In contrast,  KSL populations from IRF-2-/-  mouse bone marrow
in the stromal  environment  of  the recipient  wild-type mice still  show the phenotype of
IRF-2-/-  mice.  CD150+CD48-KSL HSCs in  untreated mice  are  predominantly  in  a  quies‐
cent intracellular Ki67-negative G0 phase. After injection of poly (I:C), most of these cells
exit G0 and enter G1, activating the cell cycle. CD150+CD48-KSL in IRF-2-/- mice contin‐
uously enter an active cell-cycle state,  which is dependent on chronic type I IFN signal‐
ing (Figure 3).
Figure 3. Chronic IFN stress in IRF-2-/- mice. In IRF-2-/- mice bone marrow cells, which cannot abrogate chronic IFN
stimulation, Sca-1 is upregulated at the mRNA and protein levels, resulting in enhanced Sca-1 on the cell surface.
However, CD150+CD48- cells are almost absent in the KSL of IRF-2-/- mouse bone marrow. Chronic IFN-α stimulation
induces cell cycle entry of dormant and homeostatic HSCs as well as progenitors (MPPs).
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Most  interestingly,  several  hematologic  malignancies,  including  acute  myeloid  leukemia
(AML) and chronic myeloid leukemia (CML), often contain a small population of malig‐
nant  cells  that  show  similarities  in  phenotype  and  function  to  normal  HSCs.  Dormant
HSCs, which show the highest self-renewal potential of all HSCs and are almost perma‐
nently  in  the  G0 phase  of  the  cell  cycle,  are  resistant  to  antiproliferative  chemotherapy
with agents,  such as  5-FU.  Cancer  stem cells  (CSCs)  are  resistant  to  radiation and anti‐
proliferative chemotherapeutic agents because of their distinctive properties, which seem
to be related to their stem cell-like character [17].
AML stem cells  are  reported to  be  located at  the  endosteal  region of  the  bone marrow
and  are  mainly  noncycling.  The  tyrosine  kinase  inhibitor  imatinib  mesylate  (Gleevec)
blocks  the  constitutively  active  BCR-ABL kinase  produced by  the  Philadelphia  chromo‐
some and is  the first  example of  targeted chemotherapy as  it  acts  against  the causative
mutation  (BCR-ABL)  that  initiates  the  disease  [18,19].  IFN-α  was  formerly  a  first-line
treatment  for  CML,  with  variable  outcomes.  Imatinib  mesylate  has  replaced IFN-α ow‐
ing to its better response rate and fewer side effects. However, intrinsic IFN-α may help
the molecular agents that target cancer stem cells.
4. Effect of IFN-γ signaling in bone marrow
IFN-γ plays a critical role in innate immunity to intracellular pathogens, including the ehrli‐
chiae, and is essential for host defense because of its ability to activate macrophages and pro‐
mote Th1 responses. Many in vivo infectious studies have demonstrated that numerous
pathogens induce production of IFN-γ, which mediates host defense. IFN-γ is a critical defense
against mycobacteria, as mice with a disrupted IFN-γ receptor gene, IFNGR-1, did not respond
to M. avium infection [20]; and human patients with mutations in the IFN-γ receptor have died
from disseminated M. avium infection [21]. However, a lesser known function of IFN-γ is its
ability to act as a moderator of hematopoiesis. Several studies have demonstrated that IFN-γ
inhibits formation of human bone marrow colonies and the growth of CD34+ bone marrow
cells through differentiation and apoptosis [22–26]. In vitro, the addition of exogenous IFN-
γ significantly inhibits myeloid and erythroid colony formation in both murine and human
systems [22,27–30]. Zhao et al. demonstrated that IFN- is essential for the generation of a unique
progenitor population that gives rise to mostly myeloid cells [31]. A colony-forming unit (CFU)
assay indicated that treatment with IFN-γ led to a reduction in the number of progenitor cells
(Lin-c-Kit+Sca-1-) in bone marrow and enhanced them in the spleen [30]. Sorted KSL cells from
IFN-γ-treated mice had greater potential for proliferation and were able to yield higher CFUs
compared to control progenitor and KSL cells.
Genes induced by IFN-γ are critical for HSC survival and maintenance via the expansion and
proliferation of KSL [20,32]. This observation shows that IFN-γ modulates the differentiation
of hematopoietic progenitor cells, resulting in the enhanced production of mature blood cells.
Investigations of mycobacterial infection have defined an important role for IFN-γ in myelo‐
poiesis [20,33–35]. Several bacterial and viral infection models have confirmed the effect of
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IFN-γ on hematopoietic stem and progenitor cells (HSPCs). A murine in vivo infection model
and in vitro human cell culture study showed that Escherichia coli stimulates the expansion and
mobilization of hematopoietic progenitors (CD34-positive cells in humans and KSL cells in a
murine system) [36–39]. Vaccinia virus infection increases immature myelocytes in peripheral
blood [10]. These infections trigger the mobilization and differentiation of common myeloid
progenitors. Intracellular bacterial infections cause the differentiation of hematopoietic pro‐
genitor cells through direct IFN-γ signaling (Figure 4).
Figure 4. During infection, IFN-γ is produced by several immune cells such as macrophages, NK cells, and lymphocytes.
IFN-γ activates HSCs and induces the expansion of MPPs.
Acute bacterial infection (Ehrlichia muris) induces myelopoiesis that is dependent on IFN-
γ signaling. It has been demonstrated that infection-induced IFN-γ acts on normally qui‐
escent HSCs, leading to transient activation and promoting an expedited innate immune
response  [7,8].  Infection  of  mice  with  the  malaria  parasite  Plasmodium  chabaudi  caused
anemia and a decrease in erythrocytes. Malarial infection induces IL-7Ra+c-Kithi  progeni‐
tors,  which  generate  myeloid  cells  to  decrease  parasitemia  in  vivo.  Lin-IL-7Ra+c-Kithi
cells contribute to the clearance of malaria-infected erythrocytes in vivo. The infection of
ifngr-/-  mice with P.  chabaudi  did not  increase the number of  Lin-IL-7Ra+c-Kithi  atypical
progenitors  [34].  Thus,  IFN-γ  signaling  is  important  for  hematopoiesis  and  the  innate
immune system’s response to acute infection.
Chronic mycobacterial infection also induces the proliferation of HSCs. M. avium infection
seems to induce an increase in the proliferative fraction of primitive LT-HSCs and a substantial
increase in the number of early-committed progenitors. IFN-γ is strongly upregulated during
M. avium infection. HSCs from Stat-1-/- and ifngr-/- mice infected with M. avium showed an
impaired proliferative response by the LT-HSC population, indicating that the HSC response
to M. avium infection is dependent on IFN-γ signaling [33]. The effects of both in vitro and in
vivo IFN-γ treatment on KSL expansion were greatly reduced in Stat-1-/- and ifngr-/- mice
compared to those in control mice [31]. Enhanced incorporation of BrdU into LT-HSCs from
IFN-γ-treated mice and a modest impairment of the engraftment of whole bone marrow cells
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in IFN-γ-treated mice were detected [33]. IFN-γ directly affects and modulates the proliferation
and mobilization of HSCs.
4.1. Human diseases and IFN-γ signaling
Human bone marrow failure syndromes, such as myelodysplastic syndromes (MDS), aplastic
anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are characterized by a defect
of stem and progenitor cell populations. The gene expression analysis of human CD34 cells
treated with IFN-γ indicated results that were similar to those of CD34 cells that are derived
from patients with bone marrow failure syndromes, according to Zheng et al. [40]. IFN-γ neg‐
atively modulates the self-renewal of CD34+CD38- stem cells and promotes differentiation of
CD34+ cord blood cells expanded in vitro [26]. IFN-γ is an important modulator of myeloid
differentiation in myelocytopenias and pathogenesis.
 
Figure 5. IFN-γ stimulation induces expression of IRF-2 and IRF-1 in mouse hematopoietic stem/progenitor cells. Bone
marrow cells from mice injected with 5-FU (150 mg/kg) were cultured in the presence of IFN-γ at the indicated con‐
centrations. Real-time PCR was performed and the relative amounts of mRNA from the IRF-1 and IRF-2 genes were
quantified with a β-actin primer [44].
4.2. IFN-γ signaling and megakaryopoiesis
IFN-γ has been reported to induce production of megakaryocytes and platelets [41,42]. A pre‐
vious study reported that IFN-γ accelerates megakaryocyte differentiation and IRF-1 and IRF-2
are IFN-γ-inducible factors that enhance megakaryopoiesis [43–45]. Huang et al. reported that
GATA-1 promotes megakaryopoiesis through the activation of IFN-γ/STAT-1 signaling, of
which IRF-1 is a downstream target. IFN-γ enhanced colony formation and proliferation of
megakaryocytes, but not their maturation [43]. When IFN-γ was stimulated with bone marrow
cells isolated from 5-FU-injected mice, IRF-2 expression was increased by around 80-100%, but
its induction level was much lower than that of IRF-1 (Fig. 5). Transduction of IRF-2 into mouse
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bone marrow stem/progenitor cells induces megakaryocyte differentiation, as we demonstrat‐
ed with a colony formation assay [44]. Upregulation of IRF-2 by IFN-γ treatment leads to CD41
expression, resulted in megakaryopoiesis [44]. IRF-2 plays an important role for hematopoiesis
mediated by each type I and type II IFN response. However, the number of peripheral blood
platelets is comparable between control mice and mice transplanted with IRF-2-transduced
bone marrow stem cells/progenitors. IRF-2 enhances megakaryocyte colony formation, not its
maturation, suggesting its cooperation with other factors for maturation [44, 45].
5. Conclusion
HSCs might be driven to exhaustion by IFN stimulation. IFN-γ modulates HSCs differentiation
into progenitors for host defense against extrinsic pathogen, inflammation, and other immune
responses. IFN-α/β stimulates quiescent/dormant HSCs to proliferate, leading to HSC exhaus‐
tion. Under conditions of chronic IFN stimulation including inflammation, infection, and IRF-2
deficiency, not only hematopoietic stem cells, but also cancer stem cells change from their
dormant status and enter the cell cycle to proliferate. Many anticancer therapies, such as 5-FU,
can disrupt proliferating cells, but not quiescent cells. Furthermore, cancer cells sometimes
become resistant to drugs with molecular targets, such as imatinib. Targeting specific intrinsic
IFN signaling in conjunction with the use of anticancer drugs may be a useful approach for
abrogating cancer stem cells.
Acknowledgements
I thank Drs. I. Hamaguchi, K. Takizawa, T. Mizukami, M. Kuramitsu, H. Momose, and K.
Yamaguchi for their experimental support and useful discussions. I wish to also thank Ms. K.
Furuhata for cell sorting and Ms. M. Tsuruhara and Ms. K.Araki for molecular technical as‐
sistance. This work was supported in part the Japan Society for the Promotion of Science and
the Ministry of Education, Science, Sports, and Culture of Japan.
Author details
Atsuko Masumi*
Address all correspondence to: amasumi@nih.go.jp
Department of Safety Research on Blood and Biological Products, National Institute of Infec‐
tious Diseases, Tokyo, Japan




[1] Ema, H, Morita, Y, Yamazaki, S, Matsubara, A, Seita, J, Tadokoro, Y, Kondo, H, Takano,
H, & Nakauchi, H. Adult Mouse Hematopoietic Stem Cells: Purification and Single-
Cell Assays. Nature Protocols (2006). , 1, 2979-2987.
[2] Orkin, S. H, & Zon, L. I. Hematopoiesis: An Evolving Paradigm for Stem Cell Biology.
Cell (2008). , 132, 631-644.
[3] Arai, F, & Suda, T. (2007). Maintenance of Quiescent Hematopoietic Stem Cells in the
Osteoblastic Niche. Annals of the New York Academy of Sciences 2007;, 1106, 41-53.
[4] Orford, K. W, & Scadden, D. T. Deconstructing Stem Cell Self-Renewal: Genetic Insights
into Cell-Cycle Regulation. Nature Reviews Genetics (2008). , 9, 115-128.
[5] Majeti, R, Park, C. Y, & Weissman, I. L. Identification of a Hierarchy of Multipotent
Hematopoietic Progenitors in Human Cord Blood. Cell Stem Cell (2007). , 1, 635-645.
[6] Mcdermott, S. P, Eppert, K, Lechman, E. R, Doedens, M, & Dick, J. E. Comparison of
Human Cord Blood Engraftment between Immunocompromised Mouse Strains. Blood
(2010). , 116, 193-200.
[7] MacNamara KCJones M, Martin O, Winslow GM. Transient Activation of Hemato‐
poietic Stem and Progenitor Cells by IFN-gamma during Acute Bacterial Infection.
PLoS One (2011). e28669. DOI:10.1371/journal.pone.0028669.
[8] MacNamara KCOduro K, Martin O, Jones DD, McLaughlin M, Choi K, D.L. Borjesson,
G.M. Winslow. Infection-induced Myelopoiesis during Intracellular Bacterial Infection
is Critically Dependent Upon IFN-Gamma Signaling. Journal of Immunology 186;
(2011). , 2011, 1032-1043.
[9] Scumpia, P, Kely-scumpia, K, Delano, M, Weinstein, J, Cuenca, A, Al-quran, S, Bovio,
I, Akira, S, Kumagai, Y, & Moldawer, L. Bacterial Infection Induces Hematopoietic Stem
and Progenitor Cell Expansion in the Absence of TLR Signaling. Journal of Immunology
(2010). , 184, 2247-2251.
[10] Singh, P, Yao, Y, Weliver, A, Broxmeyer, H, Hong, S, & Chang, C. Vaccinia Virus In‐
fection Modulates the Hematopoietic Cell Compartments in the Bone Marrow. Stem
Cells (2008). , 26, 1009-1016.
[11] Welner, R. S, Pelayo, R, Nagai, Y, Garrett, K. P, Wuest, T. R, Carr, D. J, Borghesi, L. A,
Farrar, M. A, & Kincade, P. W. Lymphoid Precursors are directed to Produce Dendritic
Cells as a Result of TLR9 Ligation during Herpes Infection. Blood (2008). , 112,
3753-3761.
[12] Kiladjian, J. J, Mesa, R. A, & Hoffman, R. The renaissance of interferon therapy for the
treatment of myeloid malignancies, Blood (2011). , 117(2011), 4706-4715.
Stem Cell Biology in Normal Life and Diseases74
[13] Taniguchi, T, Ogasawara, K, Takaoka, A, & Tanaka, N. IRF Family of Transcription
Factors as Regulators of Host Defense. Annual Review Immunology (2001). , 19,
623-655.
[14] Essers, M, Offner, S, Blanco-bose, W, Waibler, Z, Kalinke, U, Duchosal, M, & Trumpp,
A. IFNa Activates Dormant Hematopoietic Stem Cells In Vivo. Nature (2009). , 458,
904-909.
[15] Masumi, A, Miyatake, S, Kohno, T, & Matsuyama, T. Interferon Regulatory Factor-2
Regulates Hematopoietic Stem Cells in Mouse Bone Marrow. InTech-Open (2012). ,
2012, 91-112.
[16] Sato, T, Onai, N, Yoshihara, H, Arai, F, Suda, T, & Ohteki, T. Interferon Regulatory
Factor-2 Protects Quiescent Hematopoietic Stem Cells from Type 1 Interferon-Depend‐
ent Exhaustion. Nature Medicine (2009). , 15, 696-701.
[17] Van Der Wath, R. C, Wilson, A, Laurenti, E, Trumpp, A, & Lio, P. Estimating Dormant
and Active Hematopoietic Stem Cell Kinetics through Extensive Modeling of Bromo‐
deoxyuridine Label-retaining Cell Dynamics. PLoS One (2009). e6972. DOI:10.1371/
journal.pone.0006972.
[18] Goldman, J. M. Advances in CML. Clinical Advances Hematology & Oncology (2007). ,
5, 270-272.
[19] Goldman, J. M. Chronic Myeloid Leukemia Stem Cells: Now on the Run. Journal of
Clinical Oncology (2009). , 27, 313-314.
[20] Feng, C. G, Weksberg, D. C, Taylor, G. A, Sher, A, Goodell, M. A, & The, p. GTPase
Lrg-47 (Irgm1) Links Host Defense and Hematopoietic Stem Cell Proliferation. Cell
Stem Cell (2008). , 2, 83-89.
[21] Horwitz, M, Uzel, G, Linton, G, Miler, J, Brown, M, Malech, H, & Holland, S. Persistent
Mycobacterium Avium Infection Following Nonmyeloablative Allogenic Peripheral
Blood Stem Cell Transplantation for Interferon-g Receptor-1 Deficiency. Blood (2003). ,
102, 2692-2694.
[22] Hwang, J. H, Kim, S. W, Lee, H. J, Yun, H. J, Kim, S, & Jo, D. Y. Interferon Gamma has
Dual Potential in Inhibiting or Promoting Survival and Growth of Hematopoietic Pro‐
genitors: Interactions with Stromal Cell-derived Factor 1. International Journal of Hem‐
atolology (2006). , 84, 143-150.
[23] Raefsky, E. L, Platanias, L. C, Zoumbos, N. C, & Young, N. S. Studies of Interferon as
a Regulator of Hematopoietic Cell Proliferation. Journal of Immunology (1985). , 135,
2507-2512.
[24] Selleri, C, Maciejewski, J. P, Sato, T, & Young, N. S. Interferon-gamma Constitutively
Expressed in the Stromal Microenvironment of Human Marrow Cultures Mediates
Potent Hematopoietic Inhibition. Blood (1996). , 87, 4149-4157.
[25] Snoeck, H. W, Van Bockstaele, D. R, Nys, G, Lenjou, M, Lardon, F, Haenen, L, Rodrigus,
I, Peetermans, M. E, & Berneman, Z. N. Interferon-gamma Selectively Inhibits Very
Hematopoietic Stem Cells and Response to Interferon
http://dx.doi.org/10.5772/54689
75
Primitive CD342+CD38- and Not More Mature CD34+CD38+ Human Hematopoietic
Progenitor Cells. Journal of Experimental Medicine (1994). , 180, 1177-1182.
[26] Yang, L, Dybedal, I, Bryder, D, Nilsson, L, Sitnicka, E, Sasaki, Y, & Jacobsen, S. E. IFN-
gamma Negatively Modulates Self-renewal of Repopulating Human Hemopoietic
Stem Cells. Journal of Immunology (2005). , 174, 752-757.
[27] Maciejewski, J, Selleri, C, Anderson, S, & Young, N. S. Fas Antigen Expression on CD34+
Human Marrow cells is Induced by Interferon Gamma and Tumor Necrosis Factor
Alpha and Potentiates Cytokine-Mediated Hematopoietic Suppression In Vitro. Blood
(1995). , 85, 3183-3190.
[28] Sato, T, Selleri, C, Young, N, & Maciejewski, J. Hematopoietic Inhibition by Interferon-
gamma is Partially Mediated Through Interferon Regulatory Factor-1. Blood (1995). ,
86, 3373-3380.
[29] Zoumbos, N. C, Djeu, J. Y, & Young, N. S. Interferon is the Suppressor of Hematopoiesis
Generated by Stimulated Lymphocytes In Vitro. Journal of Immunology (1984). , 133,
769-774.
[30] Zoumbos, N. C, Gascon, P, Djeu, J. Y, & Young, N. S. Interferon is a Mediator of Hem‐
atopoietic Suppression in Aplastic Anemia In Vitro and Possibly In Vivo. Proceedings
of the National Academy of Sciences of the United States of America (1985). , 82, 188-192.
[31] Zhao, X, Ren, G, Liang, L, Ai, P. Z, Zheng, B, Tischfield, J. A, Shi, Y, & Shao, C. Brief
Report: Interferon-gamma Induces Expansion of Lin(-)Sca-1(+)C-Kit(+) Cells. Stem
Cells (2010). , 28, 122-126.
[32] Hartner, J. C, Walkley, C. R, Lu, J, & Orkin, S. H. ADAR1 is Essential for the Maintenance
of Hematopoiesis and Suppression of Interferon Signaling. Nature Immunology
(2009). , 10, 109-115.
[33] Baldridge, M. T, King, K. Y, Boles, N. C, Weksberg, D. C, & Goodell, M. A. Quiescent
Haematopoietic Stem cells are Activated by IFN-gamma in Response to Chronic In‐
fection. Nature (2010). , 465, 793-797.
[34] Belyaev, N. N, Brown, D. E, Diaz, A. I, Rae, A, Jarra, W, Thompson, J, Langhorne, J, &
Potocnik, A. J. Induction of an IL7-R(+)c-Kit(hi) Myelolymphoid Progenitor Critically
Dependent on IFN-gamma Signaling during Acute Malaria. Nature Immunology
(2010). , 11, 477-485.
[35] Murray, P. J, Young, R. A, & Daley, G. Q. Hematopoietic Remodeling in Interferon-
gamma-deficient Mice Infected with Mycobacteria. Blood (1998). , 91, 2914-2924.
[36] Kim, J. M, Oh, Y. K, Kim, Y. J, Youn, J, & Ahn, M. J. Escherichia Coli Up-regulates
Proinflammatory Cytokine Expression in Granulocyte/Macrophage Lineages of CD34
Stem Cells Via Homodimeric NF-kappaB. Clinical and Experimental Immunology
(2004). , 50.
Stem Cell Biology in Normal Life and Diseases76
[37] Quinton, L. J, Nelson, S, Boe, D. M, Zhang, P, Zhong, Q, Kolls, J. K, & Bagby, G. J. The
Granulocyte Colony-Stimulating Factor Response After Intrapulmonary and Systemic
Bacterial Challenges. Journal of Infectious Diseases (2002). , 185, 1476-1482.
[38] Shahbazian, L. M, Quinton, L. J, Bagby, G. J, Nelson, S, Wang, G, & Zhang, P. Escher‐
ichia Coli Pneumonia Enhances Granulopoiesis and the Mobilization of Myeloid Pro‐
genitor Cells into the Systemic Circulation. Critical Care Medicine (2004). , 32,
1740-1746.
[39] Zhang, P, Nelson, S, Bagby, G. J, & Siggins, R. nd, Shellito JE, Welsh DA. The Lineage-
c-Kit+Sca-1+ Cell Response to Escherichia Coli Bacteremia in Balb/c mice. Stem Cells
(2008). , 26, 1778-1786.
[40] Zheng, C, Li, L, Haak, M, Bros, B, Frank, O, Giehl, M, Fabarius, A, Schatz, M, Weisser,
A, Lorentz, C, Gretz, N, Hehlmann, R, Hochhaus, A, & Seifarth, W. Gene Expression
Profiling of CD34+ Cells Identifies a Molecular Signature of Chronic Myeloid Leukemia
Blast Crisis. Leukemia (2006). , 20, 1028-1034.
[41] Muraoka, K, Tsuji, K, Yoshida, M, Ebihara, Y, Yamada, K, Sui, X, Tanaka, R, & Naka‐
hata, T. Thrombopoietin-independent Effect of Interferon-gamma on the Proliferation
of Human Megakaryocyte Progenitors. British Journal of Haematology (1997). , 98,
265-273.
[42] Tsuji-takayama, K, Tahata, H, Harashima, A, Nishida, Y, Izumi, N, Fukuda, S, Ohta, T,
& Kurimoto, M. Interferon-gamma Enhances Megakaryocyte Colony-stimulating Ac‐
tivity in Murine Bone Marrow Cells. Journal of Interferon & Cytokine Research (1996). ,
16, 701-708.
[43] Huang, Z, Richmond, T, Munteen, A, Barber, D, Weiss, M, & Crispino, J. Stat1 Promotes
Megakaryopoiesis Downstream of GATA-1 in Mice. Journal of Clinical Investigation
(2007). , 117, 3890-3899.
[44] Masumi, A, Hamaguchi, I, Kuramitsu, M, Mizukami, T, Takizawa, K, Momose, H,
Naito, S, & Yamaguchi, K. Interferon Regulatory Factor-2 Induces Megakaryopoiesis
in Mouse Bone Marrow Hematopoietic Cells. FEBS Letters (2009). , 583, 3493-3500.
[45] Masumi, A. The Role for Interferon Regulatory Factor-2 on Mouse Hematopoietic Stem
Cells in an Inflammation State. Inflammation and Regeneration (2010). , 30, 531-535.
Hematopoietic Stem Cells and Response to Interferon
http://dx.doi.org/10.5772/54689
77

